AbsintaMSatiPGaitanMI, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: A new window into the inflammatory process. Ann Neurol2013; 74(5): 669–678.
2.
SatiPOhJConstableRT, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: A consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol2016; 12(12): 714–722.
3.
MaggiPAbsintaMGrammaticoM, et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol2018; 83(2): 283–294.
4.
SinneckerTClarkeMAMeierD, et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis. JAMA Neurol. Epub ahead of print 19 August 2019. DOI: 10.1001/jamaneurol.2019.2478.
5.
FilippiMPreziosaPBanwellBL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain2019; 142(7): 1858–1875.
6.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
7.
CorteseRMagnollayLTurC, et al. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology2018; 90(14): e1183–e1190.
8.
MistryNAbdel-FahimRSamaraweeraA, et al. Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions. Mult Scler2016; 22(10): 1289–1296.
9.
SolomonAJWattsROntanedaD, et al. Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. Mult Scler2018; 24(6): 750–757.
10.
BrownleeWJ.Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions: No. Mult Scler2019; 25: 768–770.
